At Revitope, with our team of creative and highly engaged scientists and industry veterans, we have engineered next-generation therapeutic T cell engagers that are active only when they bind two ...

Body cells replicate periodically (through mitosis, or cell division), but normal cells respond to their ... replicate even though this tissue doesn't need replacement cells at this time or ...

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

Weill Cornell Medicine researchers have discovered a way ovarian tumors cripple immune cells: by tampering with their ability ...

Researchers discovered that ovarian tumors hinder T cells' energy supply by trapping a key protein, blocking lipid uptake. A ...

Researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack -- blocking the energy supply T cells depend on. The work points toward a promising new ...

CD19-targeted therapies like CAR-T and T-cell engagers (TCEs) are used for B-cell malignancies, with early success in autoimmune diseases like SLE. However, TCEs face challenges due to ...

But despite causing major diseases, these slightly mutated proteins can resemble their normal versions so closely that ...

overexpressed in normal cells, such as red blood cells and cancer cells. Sino Biological has used the Beacon ® single B cell platform to screen various CD47 antibodies that bind to protein and ...

Ovarian cancer presents significant challenges due to its tumor microenvironment—a complex network of cells, molecules, and ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...